Making clinical trials more open has pros and cons for CROs and drugmakers according to experts from Amgen, Celgene, AstraZeneca, Icon and Lab Corp who spoke at an industry conference in Spain last week. The term trial transparency usually refers to a sponsor’s publication of data from all clinical studies – now a legal requirement thatnks to pressure from oragnisation's like the Alltrials group. The argument is that publication allows independent researchers to scrutinise safety and efficacy profiles of drugs in a way that improves the development of effective medicines. The drug industry has instead called for more limited data publication or “responsible transparency ,” arguing that issues like patient privacy and concerns about giving information to potential competitors as reasons for limiting disclosure. Such concerns were not in evidence at Partnerships in Clinical Trials (PCT) in Barcelona where industry speakers said that - in general - making the entire...
Integrated Drug Discovery Services- Chemistry, Biology & Preclinical Services